Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases

Experimental Neurology

Volumn 218, Issue 1, 2009, Pages 5-8

  Macauley, Shannon L ^a   Sands, Mark S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; LYSOSOME ENZYME; RECOMBINANT ENZYME;

ARTICLE; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GENE THERAPY; GENETIC DISORDER; GLOBOID CELL LEUKODYSTROPHY; HUMAN; HURLER SYNDROME; INFUSION; LYSOSOME STORAGE DISEASE; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL;

EID: 67349085201     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.03.040     Document Type: Note

References (62)

1. Achord D.A., Brot F.E., Bell C.E., and Sly W.S. Human β-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15 (1978) 269-278
2. Bankiewicz K.S., Eberling J.L., Kohutnicka M., Jagust W., Pivirotto P., Bringas J., Cunningham J., Budinger T.F., and Harvey-White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164 (2000) 2-14
3. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E., Grewel R.P., Yu K.T., and Collaborators. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Eng. J. Med. 324 (1991) 1464-1470
4. Beutler E., and Grabowski G.A. Gaucher disease. In: Scriver C.R., Beaudet AL., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw Hill, New York 3635-3668
5. Beutler E., Kay A., Saven A., Garver P., Thurston D., Dawson A., and Rosenbloom B. Enzyme replacement therapy for Gaucher disease. Blood 78 (1991) 1183-1189
6. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., and Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 2076-2080
7. Biswas S., and LeVine S.M. Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy. Pediatr. Res. 51 (2002) 40-47
8. Brooks A.I., Stein C.S., Hughes S.M., Heth J., McCray P.M., Sauter S.L., Johnston J.C., Cory-Slechta D.A., Federoff H.J., and Davidson B.L. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6216-6221
9. Cabrera-Salazar M.A., Roskelley E.M., Bu J., Hodges B.L., Yew N., Dodge J.C., Shihabuddin L.S., Sohar I., Sleat D.E., Scheule R.K., Davidson B.L., Cheng S.H., Lobel P., and Passini M.A. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol. Ther. 15 (2007) 1782-1788
10. Chang M., Cooper J.D., Sleat D.E., Cheng S.H., Dodge J.C., Passini M.A., Lobel P., and Davidson B.L. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 16 (2008) 649-656
11. Daly T.M., Lorenz R.G., and Sands M.S. Abnormal immune function in vivo in a murine model of lysosomal storage disease. Pediatr. Res. 47 (1999) 757-762
12. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., and Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 91 (2007) 61-68
13. Dodge J.C., Clarke J., Song A., Bu J., Yang W., Taksir T.V., Griffiths D., Zhao M.A., Schuchman E.H., Cheng S.H., O'Riordan C.R., Shihabuddin L.S., Passini M.A., and Stewart G.R. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17822-17827
14. Dodge J.C., Clarke J., Treleaven C.M., Taksir T.V., Griffiths D.A., Yang W., Fidler J.A., Passini M.A., Karey K.P., Schuchman E.H., Cheng S.H., and Shihabuddin L.S. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp. Neurol. 215 (2009) 349-357
15. Donsante A., Levy B., Vogler C., and Sands M.S. Clinical response to persistent, low-level β-glucuronidase expression in the murine model of mucopolysaccharidosis type VII. J. Inherit. Metab. Dis. 30 (2007) 227-238
16. Du H., Cameron T.L., Garger S.J., Pogue G.P., Hamm L.A., White E., Hanley K.M., and Grabowski G.A. Wolman disease/cholesterol ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J. Lipid. Res. 49 (2008) 1646-1657
17. Elleder M. Niemann-Pick disease. Pathol. Res. Pract. 185 (1989) 293-328
18. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N. Eng. J. Med. 345 (2001) 9-32
19. Gadola S.D., Silk J.D., Jeans A., Illarionov P.A., Salio M., Besra G.S., Dwek R., Butters T.B., Platt F.M., and Cerundolo V. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J. Exp. Med. 203 (2006) 2293-2303
20. Griffey M., Bible E., Vogler C., Levy B., Gupta P., Cooper J., and Sands M.S. Adeno associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16 (2004) 360-369
21. Griffey M.A., Wozniak D., Wong M., Bible E., Johnson K., Rothman S.M., Wentz A.E., Cooper J.D., and Sands M.S. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol. Ther. 13 (2006) 538-547
22. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorenson R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonett D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fisher A., and Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
23. Hemsley K.M., Luck A.J., Crawley A.C., Hassiotis S., Beard H., King B., Rozek T., Rozaklis T., Fuller M., and Hopwood J.J. Examination of intravenous and intra-CSF protein delivery for treatment of neurologic disease. Euro. J. Neurosci. 29 (2009) 1197-1214
24. Horinouchi K., Erlich S., Perl D., Ferlinz K., Bisgaier C., Sandhoff K., Desnick R., Stewart C., and Schuchman E. Acid sphingomyelinase defi{ligature}cient mice: a model of types A and B Niemann-Pick disease. Nat. Genet. 10 (1995) 288-293
25. Jeyakumar M., Norflus F., Tifft C.J., Cortina-Borja M., Butters T.D., Proia R.L., Perry V.H., Dwek R.A., and Platt F.M. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 97 (2001) 327-329
26. Jeyakumar M., Dwek R.A., Butters T.D., and Platt F.M. Storage solutions: treating lysosomal disorders of the brain. Nat. Rev. Neurosci. 6 (2005) 713-725
27. Jin H.K., and Schuchman E.H. Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease. Mol. Ther. 8 (2003) 876-885
28. Jin H.K., Carter J.E., Huntley G.W., and Schuchman E.H. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J. Clin. Invest. 109 (2002) 1183-1191
29. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., and Neufeld E.F. Enzyme replacement therapy in mucopolysaccharidosis I. N. Eng. J. Med. 344 (2001) 182-188
30. Kaplan A., Achord D.T., and Sly W.S. Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 2026-2030
31. 2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy. Glycobiology 15 (2005) 79-85
32. Kieler C.L., Maddox L., Bible E., Macauley S.L., Griffey M.A., Wong M., Sands M.S., and Cooper J.D. Loss of thalamic relay neurons precedes pathological effects upon the cortex of PPT1 null mutant mice. Neurobiol. Dis. 25 (2007) 150-162
33. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin like growth factor II receptors. Ann. Rev. Biochem. 61 (1992) 307-330
34. Lee W.C., Courtney A., Troendle F.J., Stallings-Mann M.L., Dickey C.A., DeLucia M.W., Dickson D.W., and Eckman C.B. Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J. 19 (2005) 1549-1551
35. Lee J.P., Jeyakumar M., Gonzalez R., Takahashi H., Lee P.J., Baek R.C., Clark D., Rose H., Fu G., Clarke J., McKercher S., Meerloo J., Muller F.J., Park K.I., Butters T.D., Dwek R.A., Schwartz P., Tong G., Wenger D., Lipton S.A., Seyfried T.N., Platt F.M., and Snyder E.Y. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat. Med. 13 (2007) 439-447
36. Lee W.C., Tsoi Y.K., Troendle F.J., DeLucia M.W., Ahmed Z., Dicky C.A., Dickson D.W., and Eckman C.B. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 21 (2007) 2520-2527
37. Lin D.S., Macauley S.L., Donsante A., Win Y., Levy B., Vogler C., and Sands M.S. Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid cell leukodystrophy. Mol. Ther. 15 (2007) 44-52
38. Lonser R.R., Walbridge S., Murray G.J., Aizenberg M.R., Vortmeyer A.O., Aerts J.M., Brady R.O., and Oldfield E.H. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann. Neurol. 57 (2005) 542-548
39. Macauley S.L., Sidman R.L., Schuchman E.H., Taksir T., and Stewart G.R. Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration. Exp. Neurol. 214 (2008) 181-192
40. Macauley, S.L., Wozniak, D.F., Kielar, C., Tan, Y., Cooper, J.D., Sands, M.S., 2009. Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. Exp. Neurol. 217, 124-135.
41. Marodi L., Kaposzta R., Toth J., and Laszlo A. Impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher disease: partial correction by enzyme replacement therapy. Blood 86 (1995) 4645-4649
42. Matzner, U., Lüllmann-Rauch, R., Stroobants, S., Andersson, C., Weigelt, C., Eistrup, C., Fogh, J., D'Hooge, R., Gieselmann, V., 2009. Enzyme Replacement Improves Ataxic Gait and Central Nervous System Histopathology in a Mouse Model of Metachromatic Leukodystrophy. Mol. Ther. 17, 600-606.
43. Meikle P.J., Hopwood J.J., Claque A.E., and Carey W.F. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
44. Miranda S.R., He X., Simonaro C.M., Gatt S., Dagan A., Desnick R.J., and Schuchman E.H. Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 14 (2000) 1988-1995
45. Neufeld E.F. Lysosomal storage diseases. Ann. Rev. Biochem. 60 (1991) 257-280
46. Neufeld E.F., and Fratantoni J.C. Inborn errors of mucopolysaccharide metabolism. Science 169 (1970) 141-146
47. Otterbach B., and Stoffel W. Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell 81 (1995) 1053-1061
48. Passini M.A., Macauley S.L., Huff M.R., Taksir T.V., Bu J., Wu I.H., Piepenhagen P.A., Dodge J.C., Shihabuddin L.S., O'Riordan C.R., Schuchman E.H., and Stewart G.R. AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol. Ther. 11 (2005) 754-762
49. Passini M.A., Dodge J.C., Bu J., Yang W., Zhao Q., Sondhi D., Hackett N.R., Kaminsky S.M., Mao Q., Shihabuddin L.S., Cheng S.H., Sleat D.E., Stewart G.R., Davidson B.L., Lobel P., and Crystal R.G. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J. Neurosci. 26 (2006) 1334-1342
50. Passini M.A., Bu J., Fidler J.A., Ziegler R.J., Foley J.W., Dodge J.C., Yang W.W., Clarke J., Taksir T.V., Griffiths D.A., Zhao M.A., O'Riordan C.R., Schuchman E.H., Shihabuddin L.S., and Cheng S.H. Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 9505-9510
51. Robbins A.R. Isolation of lysosomal α-mannosidase mutants of Chinese hamster ovary cells. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 1911-1915
52. Rome L.H., and Miller J. Butanedione treatment reduces receptor binding of a lysosomal enzyme to cells and membranes. Biochem. Biophys. Res. Comm. 92 (1980) 986-993
53. Sando G.N., and Neufeld E.F. Recognition and receptor-mediated uptake of a lysosomal enzyme, α-L-iduronidase, by cultured human fibroblasts. Cell 12 (1977) 619-627
54. Sands M.S., and Davidson B.L. Gene therapy for lysosomal storage diseases. Mol. Ther. 13 (2006) 839-849
55. Sands M.S., Vogler C., Kyle J.W., Grubb J.H., Levy B., Galvin N., Sly W.S., and Birkenmeier E.H. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J. Clin. Invest. 93 (1994) 2324-2331
56. Sands M.S., Vogler C., Torrey A., Grubb J., Levy B., Sly W.S., and Birkenmeier E.H. Murine mucopolysaccharidosis type VI: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J. Clin. Invest. 99 (1997) 1596-1605
57. Sarna J., Miranda S.R., Schuchman E.H., and Hawkes R. Patterned cerebellar Purkinje cell death in a transgenic mouse model of Niemann Pick type A/B disease. Eur. J. Neurosci. 13 (2001) 1873-1880
58. Schuchman E.H. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J. Inherit. Metab. Dis. 30 (2007) 654-663
59. Schuchman E.H., and Desnick R.J. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: Scriver C.R., Beaudet AL., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw Hill, New York 3589-3610
60. Shihabuddin L.S., Numan S., Huff M.R., Dodge J.C., Clarke J., Macauley S.L., Yang W., Taksir T.V., Parsons G., Passini M.A., Gage F.H., and Stewart G.R. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology. J. Neurosci. 24 (2004) 10642-10651
61. Ullrich K., Basner R., Gieselmann V., and Von Figura K. Recognition of human urine a-N-acetylglucosaminidase by rat hepatocytes. Biochem. J. 180 (1979) 413-419
62. Yang W.W., Dodge J.C., Passini M.A., Taksir T.V., Griffiths D., Schuchman E.H., Cheng S.H., and Shihabuddin L.S. Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse. Exp. Neurol. 207 (2007) 258-266